Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis

Abatacept disrupts T-cell coactivation signals in rheumatoid arthritis (RA). Its potential effects on B cells are not well described. This study will assess the effects of abatacept therapy on the phenotype and function of peripheral blood B cells in patients with RA.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest

Brest, 29609, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

RA as defined by ACR/EULAR criteria
Clinical indication to start abatacept therapy

Exclusion criteria

Treatment by rituximab in the previous year

Treatment and study plan

Primary outcomes

Peripheral blood B-cell phenotype changes

Time frame: 3 months

Measure of the proportion of the main B-cell subsets (transitional, naïve, memory, plasmablasts) by FACS analysis before abatacept initiation and 3 months later.

Secondary outcomes

In vitro B-cell function and regulatory properties

Time frame: 3 months

In vitro culture of B cells from the patients to assess B cell inhibition of T cell proliferation before abatacept initiation and 3 months later.

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: ABATACEPT_B

Important dates

Study start: 2014
Primary completion: 2018
Study completion: 2018
First posted: Sep 1, 2016
Registry last updated: Apr 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed